Floatz logo

Therapeutic Asset Ratings

409 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
il-15
Ovarian Cancer
Essen BiotechP1/2CC (40)
ilb2109
Ovarian Cancer
Innolake BiopharmP1/2CC (40)
Immunoglobulin G4 [237-proline,242-proline,243-valine,244-alanine,de-245-glycine], anti-(human mucin-16) (human monoclonal REGN5668 ?4-chain), disulfide with human monoclonal REGN5668 ?-chain, (235?228?),(238?231?)-bis(disulfide) with immunoglobulin G4 [230-proline,235-proline,236-valine,237-alanine,de-238-glycine,436-arginine,437-phenylalanine,446-proline] anti-(human CD28 antigen) (human monoclonal REGN5668 ?4-chain) disulfide with human monoclonal REGN5668 ?-chain
Ovarian Cancer
Regeneron PharmaceuticalsP1/2CC (40)
Inv-6452
Ovarian Cancer
Shenzhen Ionova Life Sciences Co., Ltd.P1/2CC (40)
Inv-8989
Ovarian Cancer
Shenzhen Ionova Life Sciences Co., Ltd.P1/2CC (40)
INX315
Ovarian Cancer
Incyclix BioP1/2CC (40)
Lbl-024 For
Ovarian Cancer
Nanjing Leads Biolabs Co.,LtdP1/2CC (40)
Mdna11
Ovarian Cancer
Medicenna Therapeutics, Inc.P1/2CC (40)
Metr-Nk Cell
Ovarian Cancer
Anhui Provincial Cancer HospitalP1/2CC (40)
mt-4561
Ovarian Cancer
Tanabe Pharma America, Inc.P1/2CC (40)
N-Acetyl-L-Cysteine
Ovarian Cancer
University of California, IrvineP1/2CC (40)
Neoantigen Specific Tcr-T Cell Drug Product
Ovarian Cancer
Alaunos TherapeuticsP1/2CC (40)
ngm707
Ovarian Cancer
NGM Biopharmaceuticals, IncP1/2CC (40)
Ny-Eso-1 Tcr/ Dntgfβrii
Ovarian Cancer
University of ChicagoP1/2CC (40)
Oc-Eies
Ovarian Cancer
Shenzhen Geno-Immune Medical InstituteP1/2CC (40)
Oc-Igt Cells
Ovarian Cancer
Shenzhen Geno-Immune Medical InstituteP1/2CC (40)
Palacaparib
Ovarian Cancer
AstraZenecaP1/2CC (40)
Pasifolate Exatecan
Ovarian Cancer
Elucida OncologyP1/2CC (40)
Puxitatug Samrotecan
Ovarian Cancer
AstraZenecaP1/2CC (40)
ql2107
Ovarian Cancer
Qilu Pharmaceutical Co., Ltd.P1/2CC (40)
qls5132
Ovarian Cancer
Qilu Pharmaceutical Co., Ltd.P1/2CC (40)
Rezatapopt
Ovarian Cancer
PMV Pharmaceuticals, IncP1/2CC (40)
Sacituzumab
Ovarian Cancer
Icahn School of Medicine at Mount SinaiP1/2CC (40)
SL-28
Ovarian Cancer
Second Life TherapeuticsP1/2CC (40)
Solnerstotug
Ovarian Cancer
Sensei Biotherapeutics, Inc.P1/2CC (40)
Showing 226 to 250 of 409 assets
PreviousPage 10 of 17Next